BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 17, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Adcetris brentuximab vedotin: Phase I/II started

Seattle Genetics began an open-label, U.S. Phase I/II trial to evaluate 1.8 mg/kg IV Adcetris brentuximab given once each 3-week cycle plus bendamustine in up to 50 Hodgkin's lymphoma patients after first relapse. Patients will receive up to 6 cycles of the combination followed by Adcetris monotherapy for up to 16 cycles. Adcetris has accelerated approval from FDA and conditional approval from the European Commission for relapsed...

Read the full 312 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >